Longeveron Inc（LGVN）の財務LGVNLongeveron Inc

Longeveron Inc (LGVN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical trial revenue, accounting for 95.0% of total sales, equivalent to $378.00K. Another important revenue stream is Contract manufacturing lease revenue. Understanding this composition is critical for investors evaluating how LGVN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Longeveron Inc maintains a gross margin of 63.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2150.17%, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LGVN converts its operational activities into shareholder value.

In the context of the broader market, LGVN competes directly with industry leaders such as ESLA and IGC. With a market capitalization of $23.59M, it holds a significant position in the sector. When comparing efficiency, LGVN's gross margin of 63.41% stands against ESLA's N/A and IGC's 18.11%. Such benchmarking helps identify whether Longeveron Inc is trading at a premium or discount relative to its financial performance.

Longeveron reported a net loss of $6.1 million for Q2 2026, a 22% increase from the previous year, alongside a total revenue of only $0.3 million, which is down 10% year-over-year. The gross margin has also decreased to 63.41% in Q2 2026, reflecting financial strain.